| pubmed-article:10705305 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10705305 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:10705305 | lifeskim:mentions | umls-concept:C0085669 | lld:lifeskim |
| pubmed-article:10705305 | lifeskim:mentions | umls-concept:C0194037 | lld:lifeskim |
| pubmed-article:10705305 | lifeskim:mentions | umls-concept:C0677874 | lld:lifeskim |
| pubmed-article:10705305 | lifeskim:mentions | umls-concept:C1522405 | lld:lifeskim |
| pubmed-article:10705305 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:10705305 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10705305 | pubmed:dateCreated | 2000-4-5 | lld:pubmed |
| pubmed-article:10705305 | pubmed:abstractText | Immunological control of acute leukemia may be achieved after allogeneic transplant. Despite promising preliminary results, the impact of immunotherapy with interleukin-2 (r-IL-2) on patients with acute leukemia (AL), in first complete remission (CR1) remains unclear. We conducted a prospective multicenter randomized trial to compare outcome in patients with AL in CR1, treated with autologous bone marrow transplantation (BMT) with or without postgraft r-IL-2. One hundred and thirty patients with AL in CR1 (myeloblastic (AML): N = 78; lymphoblastic (ALL): N = 52) were randomized at time of BMT to receive (N = 65) or not (N = 65) r-IL-2. r-IL-2 (RU 49637 from Roussel Uclaf) was started after hematological recovery, as a five cycle regimen (12 M IU/m2/day continuous infusion on day 1-5, 15-17, 29-31,43-45 and 57-59). The two groups were balanced for patient and transplant characteristics. Analysis was based on an intent to treat. Thirty-eight (59%) of the 65 patients randomized into the study group started r-IL-2 at a median of sixty-eight days (23-140) after transplant and received 77% (16-100) of the scheduled dosage. They received a median of 120 x 10(6) IU/m2 (25-156) over 10 (3-13) days during a total median period of 56 (3-78) days. With a median follow-up of 7 years (5.4-8.1 years), 79 patients relapsed (study group: 43 (66%); control group: 36 (55%): p = NS). Survival and leukemia-free survival estimates were 33% (23-45) versus 43% (22-52) and 29% (19-41) versus 36% (24-51) respectively for study and control groups (all p = NS). These results show that leukemic control after autologous BMT is not increased by r-IL-2 therapy. Further studies should investigate more appropriate r-IL-2 schedules and the possibilities offered by better antigen recognition and activated effector cells. | lld:pubmed |
| pubmed-article:10705305 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10705305 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10705305 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10705305 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10705305 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10705305 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10705305 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10705305 | pubmed:issn | 1148-5493 | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:NagoHH | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:AttarSS | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:SottoJ JJJ | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:MarisFF | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:MichalletMM | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:ReiffersJJ | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:BlaiseDD | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:MaraninchiDD | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:PayerGG | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:RossiJ FJF | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:BrandelyMM | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:BouabdallahRR | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:HercendTT | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:StoppaA MAM | lld:pubmed |
| pubmed-article:10705305 | pubmed:author | pubmed-author:BellangerCC | lld:pubmed |
| pubmed-article:10705305 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10705305 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:10705305 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10705305 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10705305 | pubmed:pagination | 91-8 | lld:pubmed |
| pubmed-article:10705305 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:meshHeading | pubmed-meshheading:10705305... | lld:pubmed |
| pubmed-article:10705305 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10705305 | pubmed:articleTitle | Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. | lld:pubmed |
| pubmed-article:10705305 | pubmed:affiliation | Unité de Transplantation et de Thérapie Cellulaire, Université de la Méditerranée, Institut Paoli-Calmettes, 232, bd Sainte-Marguerite, 13273 Marseille Cedex 9 France. blaised@marseille.fnclcc.fr | lld:pubmed |
| pubmed-article:10705305 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10705305 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10705305 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10705305 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:10705305 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:10705305 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10705305 | lld:pubmed |
